Blueprint Medicines Corporation
BPMC
$88.80
$2.863.33%
| Weiss Ratings | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.27 | |||
| Price History | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -6.79% | |||
| 30-Day Total Return | -5.60% | |||
| 60-Day Total Return | 0.51% | |||
| 90-Day Total Return | -6.13% | |||
| Year to Date Total Return | 1.83% | |||
| 1-Year Total Return | -3.01% | |||
| 2-Year Total Return | 99.46% | |||
| 3-Year Total Return | 32.16% | |||
| 5-Year Total Return | 47.04% | |||
| 52-Week High % Change | -29.50% | |||
| 52-Week Low % Change | 6.53% | |||
| Price | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $121.90 | |||
| 52-Week Low Price | $80.68 | |||
| 52-Week Low Price (Date) | Oct 29, 2024 | |||
| 52-Week High Price (Date) | Jul 16, 2024 | |||
| Valuation | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 5.49B | |||
| Enterprise Value | 5.35B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.07 | |||
| Earnings Per Share Growth | -87.18% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 10.74 | |||
| Price/Book (Q) | 18.33 | |||
| Enterprise Value/Revenue (TTM) | 10.52 | |||
| Price | $88.80 | |||
| Enterprise Value/EBITDA (TTM) | -27.34 | |||
| Enterprise Value/EBIT | -25.24 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 63.60M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (617) 374-7580 | |||
| Address | 45 Sidney Street Cambridge, MA 02139 | |||
| Website | www.blueprintmedicines.com | |||
| Country | United States | |||
| Year Founded | 2008 | |||
| Profitability | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -41.67% | |||
| Profit Margin | -13.18% | |||
| Management Effectiveness | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -11.89% | |||
| Return on Equity | -- | |||
| Income Statement | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 508.82M | |||
| Total Revenue (TTM) | 508.82M | |||
| Revenue Per Share | $8.00 | |||
| Gross Profit (TTM) | 488.66M | |||
| EBITDA (TTM) | -195.75M | |||
| EBIT (TTM) | -212.05M | |||
| Net Income (TTM) | -67.09M | |||
| Net Income Avl. to Common (TTM) | -67.09M | |||
| Total Revenue Growth (Q YOY) | 103.41% | |||
| Earnings Growth (Q YOY) | 54.96% | |||
| EPS Diluted (TTM) | -1.07 | |||
| EPS Diluted Growth (Q YOY) | 56.88% | |||
| Balance Sheet | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 615.49M | |||
| Cash Per Share (Q) | $9.68 | |||
| Total Current Assets (Q) | 742.68M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 298.67M | |||
| Current Ratio (Q) | 2.848 | |||
| Book Value Per Share (Q) | $4.69 | |||
| Total Assets (Q) | 1.18B | |||
| Total Current Liabilities (Q) | 260.80M | |||
| Total Debt (Q) | 724.28M | |||
| Total Liabilities (Q) | 881.15M | |||
| Total Common Equity (Q) | 298.67M | |||
| Cash Flow | BPMC - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -47.50M | |||
| Cash from Financing (TTM) | 273.11M | |||
| Net Change in Cash (TTM) | 32.12M | |||
| Levered Free Cash Flow (TTM) | -83.58M | |||
| Cash from Operations (TTM) | -192.59M | |||
